Heterologous vaccine interventions: boosting immunity against future pandemics

被引:0
|
作者
Daniela Marín-Hernández
Douglas F. Nixon
Nathaniel Hupert
机构
[1] Weill Cornell Medicine,Division of Infectious Diseases, Department of Medicine
[2] Belfer Research Building,Department of Population Health Sciences
[3] Weill Cornell Medicine,Cornell Institute for Disease and Disaster Preparedness
[4] Weill Cornell Medicine,undefined
来源
Molecular Medicine | 2021年 / 27卷
关键词
Vaccine; Non-specific immunity; Innate immunity; Trained immunity; BCG; Influenza vaccine; Vaccination; Heterologous;
D O I
暂无
中图分类号
学科分类号
摘要
While vaccines traditionally have been designed and used for protection against infection or disease caused by one specific pathogen, there are known off-target effects from vaccines that can impact infection from unrelated pathogens. The best-known non-specific effects from an unrelated or heterologous vaccine are from the use of the Bacillus Calmette-Guérin (BCG) vaccine, mediated partly through trained immunity. Other vaccines have similar heterologous effects. This review covers molecular mechanisms behind the heterologous effects, and the potential use of heterologous vaccination in the current COVID-19 pandemic. We then discuss novel pandemic response strategies based on rapidly deployed, widespread heterologous vaccination to boost population-level immunity for initial, partial protection against infection and/or clinical disease, while specific vaccines are developed.
引用
收藏
相关论文
共 50 条
  • [31] Prospects for a vaccine against Chlamydia genital disease .2. Immunity and vaccine development
    Rank, RG
    Bavoil, PM
    BULLETIN DE L INSTITUT PASTEUR, 1996, 94 (01): : 55 - 82
  • [32] Past Life and Future Effects - How Heterologous Infections Alter Immunity to Influenza Viruses
    Souquette, Aisha
    Thomas, Paul G.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [33] Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States
    Safdar, Salman
    Ngonghala, Calistus N.
    Gumel, Abba B.
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2023, 20 (01) : 179 - 212
  • [34] Long duration of immunity against a type 1 heterologous PRRS virus challenge in pigs immunised with a novel PRRS MLV vaccine: a randomised controlled study
    Jeremy Kroll
    Mike Piontkowski
    Poul H. Rathkjen
    Francois-Xavier Orveillon
    Christian Kraft
    Oliver G. Duran
    Porcine Health Management, 4
  • [35] Long duration of immunity against a type 1 heterologous PRRS virus challenge in pigs immunised with a novel PRRS MLV vaccine: a randomised controlled study
    Kroll, Jeremy
    Piontkowski, Mike
    Rathkjen, Poul H.
    Orveillon, Francois-Xavier
    Kraft, Christian
    Duran, Oliver G.
    PORCINE HEALTH MANAGEMENT, 2018, 4
  • [36] Models of Protective Immunity against Schistosomes: Implications for Vaccine Development
    Wilson, R. Alan
    PATHOGENS, 2023, 12 (10):
  • [37] Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
    Clemens, Sue Ann Costa
    Milan, Eveline Pipolo
    Sprinz, Eduardo
    Neto, Jose Cerbino
    Pacciarini, Filippo
    Li, Ping
    Chen, Hui-Ling
    Smolenov, Igor
    Pollard, Andrew
    Clemens, Ralf
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (08):
  • [38] Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?
    Basak, Preetam
    Sachdeva, Naresh
    Dayal, Devi
    BIOESSAYS, 2021, 43 (03)
  • [39] Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Guerin vaccine: mechanisms, challenges and perspectives
    Sohrabi, Yahya
    Dos Santos, Jessica Cristina
    Dorenkamp, Marc
    Findeisen, Hannes
    Godfrey, Rinesh
    Netea, Mihai G.
    Joosten, Leo A. B.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2020, 9 (12)
  • [40] Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis
    West, Nicholas P.
    Thomson, Scott A.
    Triccas, James A.
    Medveczky, C. Jill
    Ramshaw, Ian A.
    Britton, Warwick J.
    VACCINE, 2011, 29 (44) : 7759 - 7765